<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600353</url>
  </required_header>
  <id_info>
    <org_study_id>10862</org_study_id>
    <nct_id>NCT00600353</nct_id>
    <nct_alias>NCT00631930</nct_alias>
  </id_info>
  <brief_title>Multi-day Doses in Prevention of Nausea and Emesis</brief_title>
  <official_title>Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose
      dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma
      undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in
      Cancer (MASCC) Antiemesis Tool (MAT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of high doses of chemotherapy and autologous stem cell transplant has been shown to
      prolong disease control among patients with multiple myeloma and patients with lymphomas that
      have relapsed or recurred. Patients who receive autologous stem cell transplants have their
      own stem cells collected and stored prior to receiving high-dose chemotherapy, the stem cells
      are then given back to the patient as a transplant. However, the use of high doses of
      chemotherapy is associated with significant side effects of nausea and vomiting. Before the
      use of newer medications, the incidence of nausea and vomiting could be as high as 70-90%.

      Nausea is an unpleasant feeling and awareness of the urge to vomit. Vomiting is the process
      of throwing up forcefully the contents of the stomach. Retching is an act similar to vomiting
      but do not produce throwing up of the contents of the stomach. It is also called &quot;dry
      heaves&quot;.

      There are three kinds of nausea and vomiting associated with chemotherapy. Acute nausea
      and/or vomiting occur within the first 24 hours after administration of chemotherapy. Delayed
      nausea and/or vomiting begins after the first 24 hours of chemotherapy and could last for
      several days afterwards. Anticipatory nausea/vomiting is experienced prior to administration
      of the subsequent chemotherapy.

      Chemotherapy produces nausea and vomiting by damaging the cells lining the stomach and
      intestines which results in the release a substance called serotonin. The serotonin binds to
      a protein or &quot;receptor&quot; (5-HT3 receptor) in the lining of the intestines. The receptors then
      send a message to the vomiting center in the brain. The brain then sends signals to the body
      to produce nausea and vomiting.

      Another substance, called substance P, is also released from the lining of the stomach and
      intestines with damage by chemotherapy, and is released together with serotonin. The
      substance P binds to another protein called &quot;neurokinin-1 receptor&quot; or NK-1 receptor. These
      proteins are found in the intestines and another portion of the brain called &quot;tractus
      solitarius&quot;. The brain then signals the body to produce nausea and vomiting.

      The stimulation of the serotonin proteins results in acute nausea and vomiting. The
      stimulation of the NK-1 protein results in delayed nausea and vomiting.

      There are medications that could block the serotonin and NK-1 proteins. Serotonin blockers
      such as ondansetron or Zofran® are now considered the medications of choice to prevent and
      treat nausea and vomiting in the transplant setting. However, their use could still result in
      nausea and vomiting in up to 40-50% of patients.

      Nausea and vomiting negatively impacts the quality of life of patients undergoing stem cell
      transplant for their multiple myeloma and lymphoma. It can affect their appetite and sleep;
      and can interfere with activity, social life and enjoyment of life. Therefore, it is
      important to find better ways to prevent and control nausea and vomiting associated with
      chemotherapy.

      There are two new medications that are available for patients who receive regular doses of
      chemotherapy. One is the long acting preparation of the serotonin blocker called palonosetron
      or Aloxi®. It is used to control both acute and delayed nausea and vomiting. Another
      medication could block the NK-1 receptor, and is called aprepitant or Emend®. This prevents
      delayed nausea and vomiting.

      Although these two medications are tested and proven to be effective among patients who
      receive regular doses of chemotherapy, they have not been tested in combination among
      patients who undergo high doses of chemotherapy in the setting of autologous stem cell
      transplant.

      The purpose of this study is to evaluate if the combination of these two medications,
      together with small doses of steroids (dexamethasone), would be effective in preventing both
      acute and delayed vomiting associated with high doses of chemotherapy and stem cell
      transplant for patients with multiple myeloma and lymphoma. The usual way to administer
      palonosetron is by single injection in the vein before chemotherapy. This is shown to be
      effective for chemotherapy given for 1 day. Since chemotherapy regimen for transplant
      requires multiple days of treatment, palonosetron will also be administered on multiple days
      thereby delivering higher doses of this drug. Aprepitant would be administered at standard
      doses. This study would assess if combining palonosetron and aprepitant as well as giving
      multiple and higher doses of palonosetron would be safe and effective in the control of
      nausea and vomiting in the setting of transplant. The study would evaluate the effect of
      combined palonosetron and aprepitant on the quality of life with regards to nausea and
      vomiting, of patients undergoing transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Emetic Response: Acute</measure>
    <time_frame>24 hours after chemotherapy</time_frame>
    <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Emetic Response: Delayed</measure>
    <time_frame>24 to 72 hours after chemotherapy</time_frame>
    <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Emetic Response: Extended</measure>
    <time_frame>72 hours after chemotherapy</time_frame>
    <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) - 0 emetic episodes, no rescue medications. Major Emetic Response (MR) - 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) - 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) - maximum NVS ≤ 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Emetic Response</measure>
    <time_frame>At leaset 24 hours to more than 72 hours after chemotherapy</time_frame>
    <description>Clinical responses were summarized using frequencies and percentages by phase, disease group, and overall. To compute emetic response by phase, the previously defined criteria were applied to each day of the three phases independently. The worst response was used to represent the response in each of these phases and overall emetic response. Overall emetic response was computed by applying the same definitions of emetic response to the entire study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Nausea and Vomiting on the Quality of Life of Patients Undergoing Autologous HSCT</measure>
    <time_frame>24 hours, Day 3, Day 7</time_frame>
    <description>To determine quality of life, subjects' responses to the modified Osoba modules were converted to a 0 - 100 scale, with higher scores indicative of better QOL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myeloma, Plasma-Cell</condition>
  <condition>Lymphoma, Malignant</condition>
  <arm_group>
    <arm_group_label>Melphalan, dexamethasone, aprepitant, palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion
Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron 0.25 mg IV over 30 seconds</description>
    <arm_group_label>Melphalan, dexamethasone, aprepitant, palonosetron</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant 125 mg PO and Aprepitant 80 mg PO</description>
    <arm_group_label>Melphalan, dexamethasone, aprepitant, palonosetron</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push</description>
    <arm_group_label>Melphalan, dexamethasone, aprepitant, palonosetron</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with multiple myeloma and lymphoma deemed by the treating institution to be
             candidates for high dose chemotherapy and autologous hematopoietic stem cell
             transplant.

          2. Both males and females are eligible.

          3. Patients should be 18 years old; multiple myeloma patients up to age 75 and lymphoma
             patients up to age 65 are eligible.

          4. Patients with Karnofsky performance status of 60% or better.

          5. Patients should have at least 2.5 x 106 cyropreserved CD34+ cells per kilogram
             available for transplantation.

          6. Patients with adequate bone marrow function as defined as ANC ≥1000 cells/mm3 ,
             platelet ≥ 75,000 cells/mm3.

          7. Lymphoma patient must have adequate renal function as defined by a calculated
             creatinine clearance of 50% measured in ml/min.

          8. The criteria for renal function does not apply for multiple myeloma patients. Multiple
             myeloma patients undergoing hemodialysis are eligible.

          9. All patients must have a MUGA scan indicating a left ventricular ejection fraction
             (LVEF) of greater or equal to 48% within 42 days prior to registration.

         10. Patients must have adequate pulmonary function as defined by room air pulse oximetry
             equal to or greater than 93%, and pulmonary function tests (FEV1 and DLCO) equal to or
             greater than 50% of predicted values.

         11. Patients with adequate hepatic function as defined by serum bilirubin lower than 2.5
             mg/dL and liver function tests to not exceed greater than 1.5x of the institutions
             ULN.

         12. All patients must be informed of the investigational nature of this study and must
             sign and give written informed consent in accordance with the institutional and
             federal guidelines.

         13. Patients must be able to complete the anti-emesis assessment questionnaire. A Spanish
             questionnaire will be available for Hispanic-speaking patients.

        Exclusion Criteria:

          1. Patients with nausea and have emetic episodes, and are receiving any anti-emetic
             medication taken within 24 hours of receiving antibiotics.

          2. Active infection involving intravenous antibiotics.

          3. Patients with known active hepatitis B and/or hepatitis C infections are excluded.

          4. Patients with known HIV infection.

          5. Primary or secondary brain neoplasms with increased intracranial pressure.

          6. Received intrathecal chemotherapy within 24 hours of first dose of conditioning
             chemotherapy.

          7. Patients who are nursing mothers or pregnant. Females of childbearing age are required
             to have a negative serum B-HCG pregnancy test 24 hours prior to enrollment on the
             study.

          8. Patients with previous malignancies at other sites except surgically treated
             nonmelanomatous skin cancers, prostate cancer or superficial cervical cancers, or
             other cancer from which the patient had been disease free for 5 or more years.

          9. Patients with uncontrolled medical problems such as diabetes mellitus, cardiac (i.e.
             congestive heart failure, coronary heart disease, arrhythmias), pulmonary hepatic and
             renal disease unless renal insufficiency is felt to be secondary to multiple myeloma,

         10. Myocardial infarction within 6 months of enrollment in the study.

         11. Major surgery within 4 weeks of enrollment.

         12. Morbid obesity (BMI&gt;40)

         13. Patients with psychiatric or central nervous systems disorders interfering with
             ability to comply with study protocol.

         14. Patients receiving therapeutic anticoagulant therapy for venous thromboembolic episode
             or other hypercoaguable states. Coumadin at 1 mg as prophylaxis for central venous
             catheter is allowed.

         15. Known hypersensitivity to 5-HT3 antagonists and Aprepitant and their components.

         16. Use of non-prescription and herbal-type medications within 72 hours of enrollment on
             the study. Their use are not allowed during the study. Multivitamins, nutritional
             supplements such as Boost, and other electrolyte replacements are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Aljitawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea</keyword>
  <keyword>cancer</keyword>
  <keyword>CINV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 patients undergoing Autologous Stem Cell Transplant (ASCT) for multiple myeloma (MM) (n=10) and relapsed lymphoma (n=10) at the University of Kansas Medical Center were enrolled. 2 patients were excluded from analysis - both patients met exclusion criteria</recruitment_details>
      <pre_assignment_details>Emetic responses were assessed by daily patient diaries and the Multinational Association for Supportive Care in Cancer Antiemetic Tool (MAT). Nausea was measured using a Nausea Visual Score (NVS) of 0 to 10 with score of 0 having no nausea. A &quot;modified&quot; Osoba module was used to assess quality of life (QOL).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A - Subjects With Multiple Myeloma</title>
          <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
        </group>
        <group group_id="P2">
          <title>Group B - Subjects With Relpased Lymphoma</title>
          <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
carmustin (BCNU) 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>history of malignancy within 5 years</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>History of prepartive regimen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 patients excluded from analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Multiple Myeloma</title>
          <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion
Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
        </group>
        <group group_id="B2">
          <title>Group B Lymphoma</title>
          <description>Includes patients with Hodgkin's Disease and Non-Hodgkin's lymphoma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>emetic response, adverse events, quality of care</title>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B2" value="9" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B3" value="9" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Emetic Response: Acute</title>
        <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
        <time_frame>24 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Subjects With Multiple Myeloma</title>
            <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
          </group>
          <group group_id="O2">
            <title>Group B - Subjects With Relpased Lymphoma</title>
            <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
carmustin (BCNU) 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Emetic Response: Acute</title>
          <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Emetic Response: Delayed</title>
        <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
        <time_frame>24 to 72 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Subjects With Multiple Myeloma</title>
            <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
          </group>
          <group group_id="O2">
            <title>Group B - Subjects With Relpased Lymphoma</title>
            <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
carmustin (BCNU) 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Emetic Response: Delayed</title>
          <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Emetic Response: Extended</title>
        <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
        <time_frame>72 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Subjects With Multiple Myeloma</title>
            <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
          </group>
          <group group_id="O2">
            <title>Group B - Subjects With Relpased Lymphoma</title>
            <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
carmustin (BCNU) 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Emetic Response: Extended</title>
          <description>Complete Control (CC) - no emetic episode in 24 hours, no rescue medications and nausea visual scale (NVS) of ≤ 2.5, Complete Emetic Response (CR) – 0 emetic episodes, no rescue medications. Major Emetic Response (MR) – 0 to 2 emetic episodes within 24 hour period with or without rescue medications.
Minor Emetic Response (mR) – 3 to 5 emetic episodes within 24 hour period with or without rescue medications.
Failure - &gt;5 emetic episodes within 24 hour period. No Significant Nausea (NSN) – maximum NVS ≤ 5.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Emetic Response</title>
        <description>Clinical responses were summarized using frequencies and percentages by phase, disease group, and overall. To compute emetic response by phase, the previously defined criteria were applied to each day of the three phases independently. The worst response was used to represent the response in each of these phases and overall emetic response. Overall emetic response was computed by applying the same definitions of emetic response to the entire study period.</description>
        <time_frame>At leaset 24 hours to more than 72 hours after chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Subjects With Multiple Myeloma</title>
            <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
          </group>
          <group group_id="O2">
            <title>Group B - Subjects With Relpased Lymphoma</title>
            <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
carmustin (BCNU) 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Emetic Response</title>
          <description>Clinical responses were summarized using frequencies and percentages by phase, disease group, and overall. To compute emetic response by phase, the previously defined criteria were applied to each day of the three phases independently. The worst response was used to represent the response in each of these phases and overall emetic response. Overall emetic response was computed by applying the same definitions of emetic response to the entire study period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Nausea and Vomiting on the Quality of Life of Patients Undergoing Autologous HSCT</title>
        <description>To determine quality of life, subjects’ responses to the modified Osoba modules were converted to a 0 – 100 scale, with higher scores indicative of better QOL</description>
        <time_frame>24 hours, Day 3, Day 7</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day +30</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Multiple Myeloma</title>
          <description>Group A: Subjects with Multiple Myeloma
Conditioning regimen, over a 7 day period, includes:
Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion</description>
        </group>
        <group group_id="E2">
          <title>Patients With Lymphoma</title>
          <description>Group B: Subjects with Lymphoma
Conditioning regimen, over a 7 day period, includes: (BEAC)
BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Abdomen NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection, Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Omar Aljitawi</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-6029</phone>
      <email>oaljitawi@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

